Analysis
Legato came out of stealth this week with $12 million from Neotribe Ventures, Listen and Village Global, and a first look at Legato Frames -- eyeglasses with patented hearing-assistance technology built into the arms. The company was founded in late 2024, TechCrunch reported.
The founding team is the story. Mehul Trivedi led the creation of Bose Frames, then ran smart eyewear efforts at EssilorLuxottica, including work on the Meta Ray-Bans. Steve Romine ran the hearing aids division at Bose and later served as COO of Audicus, a direct-to-consumer hearing care company. Between them they have shipped both halves of this product at scale, which is unusual for a seed-stage hardware company and is most of what a $12 million check at this stage is buying.
The product and the wedge
Legato Frames use an AI system to separate voices from background noise and a dual-speaker arrangement that directs sound toward the wearer while canceling roughly 99% of sound escape -- the open-ear privacy problem that has killed most audio-eyewear attempts. The target user has mild to moderate hearing loss, the segment the FDA's 2022 over-the-counter hearing aid rule opened up. Pricing is described as a fraction of traditional hearing aids and potentially eligible for vision insurance, which is a genuinely clever billing wedge: vision benefits are far more widely held than hearing benefits.
The competitive picture
Bose exited the hearing aid business in 2020 and sold its technology to Lexie. Apple turned AirPods Pro into an FDA-cleared hearing aid in 2024, which instantly became the category's gravitational center. Sonova, Demant, WS Audiology and Starkey own the prescription market at $2,000 to $6,000 per pair. Eargo and Audicus have fought over the direct-to-consumer middle with mixed financial results -- Eargo took a securities settlement and went private. Legato's differentiation is that it is not an earbud and not a hearing aid: it is the object people with hearing loss are already wearing on their face and are not embarrassed by. Stigma, not audiology, is the binding problem in this market.
What to underwrite
Two things decide this company. First, whether the acoustics genuinely work in restaurant-level noise, which is where every hearing product is actually judged. Second, whether vision insurance reimbursement is real or aspirational -- it is the difference between a $400 impulse purchase and a $150 co-pay. A fall 2026 launch means both answers arrive within months.
The market size, honestly
Roughly 30 million American adults have some degree of hearing loss and only a fraction use any device, with average adoption delayed by years after onset. The over-the-counter category the FDA opened in 2022 was supposed to close that gap and largely has not -- unit volumes disappointed, and several direct-to-consumer entrants retrenched. The reason usually cited is not price but identity: buying a hearing aid means accepting a label. Legato's wager is that a pair of glasses sidesteps that entirely, which is a marketing insight dressed as a hardware product. If it works, the addressable market is not the OTC hearing aid category, it is everyone who already wears prescription eyewear and has started asking people to repeat themselves.
